Xeljanz is a medication commonly prescribed to treat arthritis and is currently the subject of a mass tort litigation. Some of the most serious potential side effects of Xeljanz, including the possibility for blood clots, are not indicated on the warning label. Injured patients and their families have come together seeking compensation.
What Is Xeljanz?
Xeljanz (tofacitinib) is a medication that may be used to treat moderate to severe rheumatoid arthritis, as well as psoriatic arthritis. In most cases, doctors prescribe this medication to decrease pain, swelling, and tenderness in the joints. Some patients may also receive a prescription for Xeljanz if they have a bowel disease known as "ulcerative colitis."
Xeljanz was first approved by the FDA in 2012. In 2018 sales of Xeljanz and Xeljanz XR totaled approximately $1.74 billion in the United States.
The State of the Xeljanz Litigation
Researchers discovered that Xeljanz causes a host of potentially serious symptoms and adverse reactions. As a result, the manufacturers of Xeljanz and Xeljanz XR have been forced to make significant changes to the medication's label. For example, on July 30, 2019, the label was altered to reflect an association between these medications and an increased risk of sudden cardiovascular death. If Xeljanz increases the risk of sudden cardiovascular death, then it is possible this medication may increase the risk of other adverse cardiovascular events. The manufacturers also made significant changes to the dosing recommendations included on the labels for Xeljanz and Xeljanz XR.
It seems plausible that Pfizer is trying to protect itself by warning of new risks while simultaneously downplaying and/or misrepresenting the scope of these risks.
What You Need to Know
Conducting a successful mass tort campaign requires intense preparation and careful decision making. Mass Tort Nexus is now offering a Xeljanz Litigation Package designed to ensure law firms can sign every qualified client who makes an inquiry. This package suggests criteria and rationale that law firms can use to qualify clients. The Xeljanz Litigation Package will be available only to those who attend the Mass Tort Nexus 4-Day Immersion Course or the Mass Tort Nexus Alumni Day in September.
It is important to stay up-to-date on the latest Xeljanz mass tort information since it is still evolving and new issues are sure to develop. Stay tuned for updates and changes in this case.
Having sufficient intake and call answering support is essential if you are hoping to get involved in the Xeljanz mass tort or any other mass tort campaigns. Please contact Alert Communications to find out how we can make sure you never miss a lead.